Brokerages forecast that Zoetis Inc (NYSE:ZTS) will report $1.46 billion in sales for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Zoetis’ earnings, with the highest sales estimate coming in at $1.49 billion and the lowest estimate coming in at $1.43 billion. Zoetis reported sales of $1.35 billion during the same quarter last year, which indicates a positive year-over-year growth rate of 8.1%. The firm is scheduled to issue its next quarterly earnings report before the market opens on Thursday, November 1st.

According to Zacks, analysts expect that Zoetis will report full year sales of $5.78 billion for the current fiscal year, with estimates ranging from $5.73 billion to $5.80 billion. For the next fiscal year, analysts anticipate that the company will post sales of $6.28 billion, with estimates ranging from $6.16 billion to $6.36 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that cover Zoetis.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, August 2nd. The company reported $0.77 EPS for the quarter, beating the consensus estimate of $0.71 by $0.06. Zoetis had a net margin of 19.95% and a return on equity of 72.30%. The firm had revenue of $1.42 billion during the quarter, compared to the consensus estimate of $1.38 billion. During the same quarter in the prior year, the firm earned $0.53 EPS. Zoetis’s revenue for the quarter was up 11.5% on a year-over-year basis.

Several analysts recently commented on ZTS shares. Jefferies Financial Group set a $96.00 price target on shares of Zoetis and gave the company a “buy” rating in a research report on Friday, July 13th. Cantor Fitzgerald set a $98.00 price target on shares of Zoetis and gave the company a “buy” rating in a research report on Friday, July 27th. Bank of America upped their price target on shares of Zoetis from $97.00 to $100.00 and gave the company a “buy” rating in a research report on Monday, July 30th. BMO Capital Markets reiterated a “hold” rating and issued a $82.00 price target on shares of Zoetis in a research report on Thursday, August 2nd. Finally, Morgan Stanley upped their price target on shares of Zoetis from $87.00 to $92.00 and gave the company a “hold” rating in a research report on Friday, August 3rd. Seven analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $92.63.

In other Zoetis news, insider Kristin C. Peck sold 5,000 shares of the business’s stock in a transaction on Wednesday, August 1st. The shares were sold at an average price of $86.22, for a total value of $431,100.00. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Juan Ramon Alaix sold 135,000 shares of the business’s stock in a transaction on Tuesday, August 14th. The shares were sold at an average price of $91.55, for a total transaction of $12,359,250.00. The disclosure for this sale can be found here. Insiders sold a total of 213,467 shares of company stock worth $19,502,725 over the last three months. 0.35% of the stock is currently owned by corporate insiders.

Several large investors have recently bought and sold shares of the company. Valeo Financial Advisors LLC grew its stake in shares of Zoetis by 34.4% during the 2nd quarter. Valeo Financial Advisors LLC now owns 2,210 shares of the company’s stock worth $202,000 after purchasing an additional 566 shares during the period. Dupont Capital Management Corp grew its stake in shares of Zoetis by 2.5% during the 2nd quarter. Dupont Capital Management Corp now owns 24,508 shares of the company’s stock worth $2,088,000 after purchasing an additional 601 shares during the period. Dorsey Wright & Associates grew its stake in shares of Zoetis by 7.9% during the 2nd quarter. Dorsey Wright & Associates now owns 8,386 shares of the company’s stock worth $714,000 after purchasing an additional 617 shares during the period. Rehmann Capital Advisory Group grew its stake in shares of Zoetis by 40.5% during the 2nd quarter. Rehmann Capital Advisory Group now owns 2,190 shares of the company’s stock worth $187,000 after purchasing an additional 631 shares during the period. Finally, Wrapmanager Inc. grew its stake in shares of Zoetis by 7.9% during the 2nd quarter. Wrapmanager Inc. now owns 9,176 shares of the company’s stock worth $782,000 after purchasing an additional 672 shares during the period. 89.76% of the stock is currently owned by institutional investors and hedge funds.

ZTS stock opened at $91.83 on Friday. Zoetis has a 12 month low of $63.03 and a 12 month high of $94.31. The firm has a market capitalization of $44.12 billion, a P/E ratio of 38.66, a price-to-earnings-growth ratio of 1.74 and a beta of 1.01. The company has a quick ratio of 2.92, a current ratio of 4.38 and a debt-to-equity ratio of 2.50.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 3rd. Shareholders of record on Tuesday, November 20th will be paid a $0.126 dividend. The ex-dividend date is Monday, November 19th. This represents a $0.50 annualized dividend and a yield of 0.55%. Zoetis’s dividend payout ratio is currently 20.83%.

Zoetis Company Profile

Zoetis Inc discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Featured Story: What does earnings per share mean?

Get a free copy of the Zacks research report on Zoetis (ZTS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.